Joachim Ehrlich (JW Goethe University, Frankfurt) talks about the second-generation balloons used in single-shot cryoablation techniques and their efficacy over older technologies in atrial fibrillation. He also discusses the advantages of cryoablation over radiofrequency ablation; although, as the FIRE AND ICE trial showed, efficacy is similar between both techniques, cryoablation is easier to use and quicker in treating patients with paroxysmal atrial fibrillation. With the new-generation cryoballoon catheter, the speed of the procedure overall is quicker and success can be monitored online. Dr Ehrlich predicts that, due to the simplicity and ease of the cryoablation procedure, many physicians will be able to treat their patients with this technique.
Filmed at EHRA 2018, Barcelona.
1. Please can you describe any recent progress that has been made in single-shot cryoablation techniques? 0:07
2. What are the advantages of cryoablation over radiofrequency ablation and how do they differ in terms of efficacy? 0:36
3. How do the features of the new-generation cryoballoon catheter contribute to its ease of use? 1:07
4. What are the clinical implications of cryoablation and what is the impact on patient outcomes in the real world? 1:34
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!